The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's ...

Scientists have recently shown that both the quality and the amount of sleep we get may influence our risk of developing ...

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

Taking too long to enter the phase of sleep in which we dream may be an early sign of Alzheimer's disease. This is the conclusion of an international team of researchers who studied the sleep patterns ...

As research continues, those involved say this would be a game changer, especially for patients with very limited options.

A new study has revealed that the time it takes for you to reach the dream phase of sleep, known as rapid eye movement (REM) ...

Researchers believe that those who take longer to enter the dream phase of sleep may be at higher risk of Alzheimer's disease ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Recent studies have shown that both the quality and the amount of sleep we get may influence our risk of developing Alzheimer ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

A study looks at how long people live and how long before they enter a nursing home after a dementia diagnosis.